Edition:
India

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Global Select Market

3.26USD
26 Oct 2020
Change (% chg)

-- (--)
Prev Close
$3.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
301,458
52-wk High
$7.21
52-wk Low
$2.87

Latest Key Developments (Source: Significant Developments)

Biodelivery Sciences Reports Q2 Revenue Of $36.6 Mln
Wednesday, 5 Aug 2020 

Aug 5 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG Q2 2020 RESULTS.Q2 GAAP EARNINGS PER SHARE $0.01.Q2 REVENUE $36.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $36.4 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA.  Full Article

Biodelivery Sciences Reports Strong Fourth Quarter And Full-Year 2019 Results
Friday, 13 Mar 2020 

March 12 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG FOURTH QUARTER AND FULL-YEAR 2019 RESULTS.Q4 REVENUE $31.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $31 MILLION.  Full Article

BDSI Sees FY 2020 Sales $150 Million To $160 Million
Monday, 13 Jan 2020 

Jan 13 (Reuters) - BioDelivery Sciences International Inc ::BDSI EXPECTS FOURTH QUARTER AND 2019 TOTAL NET SALES AT THE HIGH END OF GUIDANCE: REPORTS SIGNIFICANTLY EXPANDED INSURANCE ACCESS FOR SYMPROIC.SEES FY 2020 SALES $150 MILLION TO $160 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - REITERATED PREVIOUSLY ANNOUNCED 2020 NET SALES GUIDANCE OF $150-$160 MILLION FOR BELBUCA, $165-$175 MILLION FOR TOTAL CO.  Full Article

Biodelivery Sciences International Expects Full Year 2020 Total Company Net Sales Of $165 Million - $175 Million
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG THIRD QUARTER RESULTS, RAISES FULL YEAR 2019 AND PROVIDES 2020 NET SALES EXPECTATIONS.Q3 REVENUE $30.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $28.3 MILLION.SEES FY 2019 SALES $105 MILLION TO $110 MILLION.PROVIDES FULL YEAR 2020 BELBUCA NET SALES EXPECTATIONS OF $150 - $160 MILLION.PROVIDES FULL YEAR 2020 TOTAL COMPANY NET SALES EXPECTATIONS OF $165 - $175 MILLION.QTRLY EARNINGS PER SHARE $0.00.AS OF SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $55.9 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.02 -- REFINITIV IBES DATA.  Full Article

Biodelivery Sciences International Q2 GAAP Loss Per Share $0.13
Friday, 9 Aug 2019 

Aug 8 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG SECOND QUARTER 2019 RESULTS AND RAISES NET SALES EXPECTATIONS.Q2 GAAP LOSS PER SHARE $0.13.Q2 REVENUE $29.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $24.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.06 -- REFINITIV IBES DATA.SEES FY 2019 SALES $101 MILLION TO $105 MILLION.RAISES LONG-TERM COMBINED NET SALES EXPECTATIONS FOR BELBUCA AND SYMPROIC TO $425 - $500 MILLION.RAISES FULL-YEAR BELBUCA NET SALES EXPECTATIONS TO $90 - $93 MILLION.ANTICIPATES HAVING POSITIVE OPERATING CASH FLOW BY Q4.  Full Article

Biopharma Credit Entered Into A Definitive Senior Secured Term Loan Agreement
Wednesday, 29 May 2019 

May 29 (Reuters) - BioDelivery Sciences International Inc ::BIOPHARMA CREDIT PLC - ENTERED INTO A DEFINITIVE SENIOR SECURED TERM LOAN AGREEMENT FOR UP TO US$80 MILLION WITH BIODELIVERY SCIENCES.BIOPHARMA CREDIT - BPCR ACQUIRED 5,000,000 BDSI SHARES AT US$5.00 EACH FOR A TOTAL COST OF US$25 MILLION IN A PUBLIC OFFERING THAT PRICED ON 11 APRIL 2019.BIOPHARMA CREDIT PLC - LOAN WILL MATURE IN MAY 2025 AND BEARS INTEREST AT LIBOR PLUS 7.5%, ALONG WITH 2% ADDITIONAL CONSIDERATION.  Full Article

BioDelivery Sciences Strengthens Financial Position With Debt Refinancing
Wednesday, 29 May 2019 

May 28 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES STRENGTHENS FINANCIAL POSITION WITH DEBT REFINANCING.BIODELIVERY SCIENCES INTERNATIONAL INC - NEW AGREEMENT IS CASH FLOW ACCRETIVE, LOWERS COST OF CAPITAL AND EXTENDS DEBT MATURITY.BIODELIVERY SCIENCES INTERNATIONAL INC - REDUCES ANNUAL INTEREST COSTS BY APPROXIMATELY $1.5 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - NEW FACILITY CONSISTS OF A $60.0 MILLION TERM LOAN.BIODELIVERY SCIENCES - PROCEEDS FROM FINANCING, AVAILABLE CASH ON HAND, USED TO REPAY & RETIRE EXISTING TERM LOAN WITH CRG SERVICING LLC.  Full Article

Biodelivery Sciences Q1 Loss Per Share $0.05
Tuesday, 7 May 2019 

May 6 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG FIRST QUARTER 2019 RESULTS AND RAISES BELBUCA® FULL-YEAR EXPECTATIONS.Q1 LOSS PER SHARE $0.05.Q1 REVENUE $19.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.SEES FY 2019 SALES $92 MILLION TO $100 MILLION.RAISES FULL-YEAR BELBUCA NET SALES EXPECTATIONS TO $83 - $88 MILLION.FY2019 REVENUE VIEW $94.6 MILLION -- REFINITIV IBES DATA.REITERATED EXPECTATION TO HAVE POSITIVE CASH FLOW FROM OPERATIONS BY YEAR END.  Full Article

Biodelivery Sciences International Announces Pricing Of Public Offering Of Common Stock
Thursday, 11 Apr 2019 

April 11 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING PRICED AT $5.00PER SHARE.  Full Article

BioDelivery Sciences International Inc Increases Belbuca 2019 Net Sales Expectations To $80 Mln-$85 Mln
Friday, 15 Mar 2019 

March 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL INC - INCREASES BELBUCA 2019 NET SALES EXPECTATIONS TO $80-$85 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC SEES OPERATING CASH FLOW TO BECOME POSITIVE IN 2019.BIODELIVERY SCIENCES INTERNATIONAL INC - LONG-TERM POTENTIAL FOR BELBUCA NET SALES BELIEVED TO BE $250-$300 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - TOTAL NET REVENUE FOR Q4 $18.0 MILLION VERSUS $14.2 MILLION IN Q3 OF 2018.BIODELIVERY SCIENCES INTERNATIONAL INC QTRLY LOSS PER SHARE $0.10.BIODELIVERY SCIENCES INTERNATIONAL INC SEES 2019 TOTAL COMPANY NET REVENUE TO BE IN RANGE OF $85-$90 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - AT DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.8 MILLION.  Full Article

BRIEF-Biodelivery Sciences Says Frank O'Donnell Jr Notified That He Has Decided To Resign

* BIODELIVERY SCIENCES INTERNATIONAL INC - FRANK E. O'DONNELL JR NOTIFIED CO THAT HE HAS DECIDED TO RESIGN Source text: (https://bit.ly/2zu0UjM) Further company coverage: